- Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
Vladimer Darsalia et al, 2019, Frontiers in Neurology CrossRef - Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
Chin-Hsiao Tseng, 2021, Frontiers in Endocrinology CrossRef - Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron
Eleni Xourgia et al, 2019, World Journal of Diabetes CrossRef - GLP-1’s role in neuroprotection: a systematic review
Damla Erbil et al, 2019, Brain Injury CrossRef - Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jiang et al, 2024, Frontiers in Pharmacology CrossRef - Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease
Devasrita Dash et al, 2022, Biomedical and Pharmacology Journal CrossRef - Targeting Insulin Resistance to Treat Cognitive Dysfunction
Anit Tyagi et al, 2021, Molecular Neurobiology CrossRef - Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents
Agnieszka Jankowska et al, 2020, Current Medicinal Chemistry CrossRef